<?xml version="1.0" encoding="UTF-8"?>
<ref id="B119-viruses-12-00862">
 <label>119.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Fotouhi</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Shaffifar</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Farahmand</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Shirian</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Saeidi</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Tabarraei</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Gorji</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Ghaemi</surname>
    <given-names>A.</given-names>
   </name>
  </person-group>
  <article-title>Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus</article-title>
  <source>Arch. Virol.</source>
  <year>2017</year>
  <volume>162</volume>
  <fpage>1251</fpage>
  <lpage>1260</lpage>
  <pub-id pub-id-type="doi">10.1007/s00705-017-3230-7</pub-id>
  <pub-id pub-id-type="pmid">28120096</pub-id>
 </element-citation>
</ref>
